Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alexander Burnett

Concepts (196)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Laparoscopy
7
2024
180
1.990
Why?
Endometrial Neoplasms
8
2024
144
1.840
Why?
Uterine Cervical Neoplasms
12
2022
299
1.650
Why?
Lymph Node Excision
5
2024
133
1.490
Why?
Neoplasm Staging
8
2024
772
0.880
Why?
Obesity, Morbid
2
2023
87
0.870
Why?
Natural Orifice Endoscopic Surgery
1
2023
5
0.870
Why?
Whole-Body Irradiation
2
2014
127
0.830
Why?
Gynecologic Surgical Procedures
4
2009
28
0.830
Why?
Sentinel Lymph Node Biopsy
1
2024
120
0.830
Why?
Metformin
2
2020
76
0.610
Why?
Hypoglycemic Agents
2
2020
211
0.580
Why?
Interleukin-11
2
2013
6
0.510
Why?
Neoplasm Recurrence, Local
3
2016
649
0.470
Why?
2-Pyridinylmethylsulfinylbenzimidazoles
1
2014
18
0.450
Why?
Prescription Drugs
1
2014
41
0.440
Why?
Uterine Neoplasms
7
2007
60
0.430
Why?
Hysterectomy
4
2023
90
0.430
Why?
Proton Pump Inhibitors
1
2014
86
0.430
Why?
Radiation Tolerance
1
2014
84
0.420
Why?
Radiation-Protective Agents
1
2013
72
0.410
Why?
Obesity
2
2016
1162
0.400
Why?
Robotics
2
2010
43
0.390
Why?
Female
33
2024
28171
0.390
Why?
Organotechnetium Compounds
1
2011
6
0.360
Why?
Lymphedema
1
2011
48
0.350
Why?
Vulvar Neoplasms
1
2011
60
0.340
Why?
Lower Extremity
1
2011
100
0.330
Why?
Radiopharmaceuticals
1
2011
204
0.330
Why?
Carcinoma, Squamous Cell
2
2011
332
0.330
Why?
Cystadenocarcinoma, Papillary
5
2006
14
0.310
Why?
Adult
20
2024
14161
0.300
Why?
Humans
35
2024
52483
0.300
Why?
Aged
17
2024
10121
0.290
Why?
Middle Aged
19
2024
13028
0.280
Why?
Fertility
2
2009
32
0.280
Why?
Retroperitoneal Space
2
2024
26
0.280
Why?
Retrospective Studies
5
2023
6607
0.270
Why?
Vagina
2
2023
46
0.270
Why?
Cervix Uteri
1
2006
49
0.250
Why?
Adenocarcinoma
1
2009
405
0.240
Why?
Topotecan
1
2005
17
0.230
Why?
Polyethylene Glycols
1
2005
90
0.220
Why?
Genital Neoplasms, Female
1
2004
48
0.220
Why?
Postoperative Complications
1
2011
1068
0.220
Why?
Neoplasms
2
2023
1325
0.220
Why?
Ovarian Neoplasms
4
2014
459
0.210
Why?
Feasibility Studies
2
2024
406
0.210
Why?
Aged, 80 and over
6
2023
3392
0.210
Why?
Doxorubicin
1
2005
241
0.210
Why?
Uterus
1
2023
88
0.210
Why?
Lymph Nodes
1
2004
258
0.200
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2007
1031
0.200
Why?
Gene Expression Regulation, Neoplastic
6
2011
857
0.190
Why?
Prospective Studies
3
2024
2481
0.170
Why?
Intestines
2
2013
154
0.160
Why?
Carcinoma
2
2011
138
0.140
Why?
Cell Proliferation
2
2020
1023
0.140
Why?
Cancer Vaccines
3
2014
78
0.140
Why?
Antineoplastic Agents
2
2007
1222
0.140
Why?
Dendritic Cells
3
2014
136
0.140
Why?
Kruppel-Like Transcription Factors
2
2020
36
0.130
Why?
Cystadenocarcinoma, Serous
3
2005
73
0.130
Why?
Enterotoxins
2
2007
12
0.130
Why?
Aromatase Inhibitors
2
2007
14
0.130
Why?
Pregnancy
1
2023
2680
0.130
Why?
Nitriles
2
2007
53
0.130
Why?
Kallikreins
2
2006
19
0.120
Why?
Mice
4
2014
5949
0.120
Why?
Triazoles
2
2007
115
0.120
Why?
Receptor, erbB-2
2
2005
80
0.120
Why?
Lethal Dose 50
1
2014
12
0.110
Why?
Medical Oncology
2
2006
104
0.110
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
1
2014
14
0.110
Why?
Hematopoiesis
1
2014
69
0.110
Why?
Hydrogen-Ion Concentration
1
2014
178
0.110
Why?
Ascites
1
2014
32
0.110
Why?
Safety
1
2014
79
0.110
Why?
Survival Analysis
2
2013
673
0.110
Why?
Treatment Outcome
4
2023
5422
0.110
Why?
Stomach
1
2014
82
0.110
Why?
Spectrometry, Fluorescence
1
2013
46
0.100
Why?
Carcinoma, Endometrioid
2
2010
38
0.100
Why?
CD4-Positive T-Lymphocytes
1
2014
164
0.100
Why?
Incidence
1
2016
1062
0.100
Why?
Administration, Oral
1
2013
451
0.100
Why?
Papillomaviridae
3
2013
105
0.090
Why?
Animals
5
2014
13505
0.090
Why?
Cytokines
1
2014
623
0.090
Why?
Male
5
2023
26761
0.080
Why?
Arkansas
1
2016
2028
0.080
Why?
Cerclage, Cervical
1
2009
8
0.080
Why?
Estrogens
1
2011
223
0.080
Why?
Gene Amplification
2
2005
58
0.080
Why?
Genes, erbB-2
2
2005
8
0.080
Why?
Adolescent
5
2023
6739
0.070
Why?
Carcinoma, Papillary
2
2005
51
0.070
Why?
Membrane Proteins
2
2007
335
0.070
Why?
Melanoma
1
2011
288
0.070
Why?
Intestinal Diseases
1
2007
26
0.070
Why?
Leiomyosarcoma
1
2007
21
0.070
Why?
Clostridium perfringens
1
2007
6
0.070
Why?
Carcinosarcoma
1
2007
18
0.070
Why?
Radiation Injuries, Experimental
1
2007
81
0.070
Why?
Endometrium
2
2020
43
0.060
Why?
Infertility, Female
1
2006
19
0.060
Why?
Oncogene Proteins, Viral
1
2005
54
0.060
Why?
Dysgerminoma
1
2004
2
0.060
Why?
Fellowships and Scholarships
1
2006
127
0.060
Why?
Medroxyprogesterone Acetate
1
2004
6
0.060
Why?
Patient Selection
1
2006
259
0.060
Why?
Gynecology
1
2004
52
0.050
Why?
Interleukin-6
1
2005
278
0.050
Why?
Case-Control Studies
2
2023
1201
0.050
Why?
Immunotherapy, Adoptive
1
2005
166
0.050
Why?
Lymphatic Metastasis
1
2004
220
0.050
Why?
England
1
2023
58
0.050
Why?
Drug Therapy, Combination
1
2005
395
0.050
Why?
Antibodies, Monoclonal
1
2007
481
0.050
Why?
Immunohistochemistry
4
2007
979
0.050
Why?
DNA-Binding Proteins
1
2005
422
0.050
Why?
Immunotherapy
1
2005
244
0.050
Why?
Cells, Cultured
3
2014
1567
0.050
Why?
Education, Medical, Graduate
1
2004
219
0.050
Why?
Lung Neoplasms
1
2007
636
0.040
Why?
Preoperative Period
1
2020
46
0.040
Why?
PTEN Phosphohydrolase
1
2020
55
0.040
Why?
Gene Expression Profiling
1
2005
1105
0.040
Why?
Receptors, Progesterone
1
2020
66
0.040
Why?
Estrogen Receptor alpha
1
2020
85
0.040
Why?
Young Adult
2
2023
4329
0.040
Why?
Cell Line, Tumor
3
2007
1470
0.040
Why?
Pilot Projects
1
2020
721
0.030
Why?
Claudin-3
2
2007
5
0.030
Why?
Claudin-4
2
2007
7
0.030
Why?
Lymphocyte Activation
2
2007
172
0.030
Why?
Mice, SCID
2
2007
182
0.030
Why?
Enzyme-Linked Immunosorbent Assay
2
2006
235
0.030
Why?
In Situ Hybridization, Fluorescence
2
2005
263
0.030
Why?
Apoptosis
1
2020
1119
0.030
Why?
Coculture Techniques
1
2014
144
0.030
Why?
p38 Mitogen-Activated Protein Kinases
1
2014
94
0.030
Why?
Human Umbilical Vein Endothelial Cells
1
2014
99
0.030
Why?
Combined Modality Therapy
2
2007
639
0.030
Why?
Optics and Photonics
1
2013
10
0.030
Why?
Antigens, Neoplasm
1
2014
147
0.030
Why?
Drug Resistance, Neoplasm
2
2005
326
0.030
Why?
Spectrum Analysis
1
2013
69
0.030
Why?
Uterine Cervical Dysplasia
1
2013
51
0.020
Why?
RNA, Messenger
2
2005
1132
0.020
Why?
Early Detection of Cancer
1
2013
189
0.020
Why?
Gene Silencing
1
2011
118
0.020
Why?
Papillomavirus Infections
1
2013
173
0.020
Why?
Prognosis
2
2005
2099
0.020
Why?
Antibody-Dependent Cell Cytotoxicity
1
2007
12
0.020
Why?
Mast Cells
1
2007
55
0.020
Why?
Neoplasm Transplantation
1
2007
87
0.020
Why?
Antineoplastic Agents, Hormonal
1
2007
53
0.020
Why?
Remission Induction
1
2007
218
0.020
Why?
Transforming Growth Factor beta
1
2007
138
0.020
Why?
Lymphocytes
1
2007
153
0.020
Why?
Intestinal Mucosa
1
2007
224
0.020
Why?
Recombinant Proteins
1
2007
483
0.020
Why?
Hypersensitivity, Delayed
1
2005
18
0.020
Why?
Papillomavirus E7 Proteins
1
2005
32
0.020
Why?
Sampling Studies
1
2005
38
0.020
Why?
Antigens, Viral
1
2005
43
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
236
0.010
Why?
Probability
1
2005
172
0.010
Why?
Injections, Intraperitoneal
1
2005
57
0.010
Why?
Paraffin Embedding
1
2005
52
0.010
Why?
Statistics, Nonparametric
1
2005
192
0.010
Why?
Biopsy, Needle
1
2005
183
0.010
Why?
Carboplatin
1
2004
57
0.010
Why?
Etoposide
1
2004
74
0.010
Why?
Xenograft Model Antitumor Assays
1
2005
220
0.010
Why?
Flow Cytometry
1
2007
478
0.010
Why?
B-Lymphocytes
1
2005
184
0.010
Why?
Chemotherapy, Adjuvant
1
2004
124
0.010
Why?
Receptors, Cell Surface
1
2005
118
0.010
Why?
Tumor Cells, Cultured
1
2005
460
0.010
Why?
Polymerase Chain Reaction
1
2005
461
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2005
582
0.010
Why?
Rats, Sprague-Dawley
1
2007
1563
0.010
Why?
Proportional Hazards Models
1
2005
443
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2005
405
0.010
Why?
T-Lymphocytes
1
2005
340
0.010
Why?
Clinical Competence
1
2006
406
0.010
Why?
Sensitivity and Specificity
1
2005
891
0.010
Why?
Survival Rate
1
2005
945
0.010
Why?
Disease-Free Survival
1
2003
460
0.010
Why?
Regression Analysis
1
2003
401
0.010
Why?
Age Factors
1
2005
1132
0.010
Why?
Rats
1
2007
3220
0.010
Why?
Risk Assessment
1
2005
1327
0.010
Why?
Child
1
2004
7248
0.010
Why?
Burnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description